NSE filing, NSE: REMUS. Summary written from the filing by ALFA Finder's alert engine.
Remus Pharmaceuticals Ltd: key numbers
- Share price
- ₹845.65
- Market cap
- ₹996.5 Cr
- Revenue (annual)
- ₹853.6 Cr
- Net profit (annual)
- ₹36.99 Cr
- P/E (TTM)
- 26.9×Sector 47.2×
- Promoter holding
- 70.95%
- FII holding
- 5.10%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Remus Pharmaceuticals Ltd
All →Remus Pharmaceuticals Dividend
Remus Pharmaceuticals has fixed 7 November 2026 as the record date for its 1st interim dividend for FY 2026-27, declared at today's board meeting. The filing does not state the per-share dividend amount.
Remus Pharmaceuticals H1 FY27 Results: Net Profit ₹24.7 Cr, Up 14.4% YoY
Remus Pharmaceuticals Ltd reported revenue from operations of ₹614.1 Cr (+53.4% YoY) and net profit of ₹24.7 Cr (+14.4% YoY) for H1 FY27.
- Key figure
- Net profit ₹24.7 Cr · +14.4% YoY
Remus Pharmaceuticals Other Announcement
Remus Pharmaceuticals filed its Reg 76 Reconciliation of Share Capital Audit Report for Q1 FY2027. It is a routine depository-compliance certificate with no transaction or business event.
Remus Pharmaceuticals Annual General Meeting
Remus Pharmaceuticals Limited shareholders approved the migration of equity shares from the NSE Emerge platform to the main boards of NSE and BSE.
Remus Pharmaceuticals Annual General Meeting
Remus Pharmaceuticals held its 11th Annual General Meeting on September 29, 2026. Shareholders discussed financial results, dividend declaration, and director appointments.
Remus Pharmaceuticals Dividend
Remus Pharmaceuticals Limited has fixed September 22, 2026, as the record date for determining shareholder entitlement to a final dividend of Rs. 0.50 per share.
Other results update announcements
All →Awfis Space Solutions Results Update
Awfis reported Q2 FY27 normalised revenue up 26% to Rs 451 Crore; cash EBITDA rose 45% to Rs 49 Crore. Strong co-working and GCC demand drove growth.
Anthem Biosciences Results Update
Anthem Biosciences reported Q2 FY27 consolidated revenue of ₹5,940 Mn, up 7.9% year-on-year, and PAT of ₹2,115 Mn. H1 FY27 PAT rose 7.2% to ₹3,314 Mn.
Aayush Wellness Results Update
Aayush Wellness reported H1 FY27 consolidated total income of ₹7,061.82 lakhs, up 10.61%. PAT rose 5.86% to ₹250.10 lakhs.
Bata India Results Update
Bata India reported Q2 revenue of Rs. 8,618 million, up 7.5%, and PAT of Rs. 180 million, up 31%. Growth continued for a fourth consecutive quarter.
Asian Granito India Results Update
Asian Granito India's press release reports consolidated Q2 FY27 revenue up 18.8% to ₹528.5 Crore. Profit after tax fell to ₹5.22 Crore amid a sharp rise in power and fuel costs.
National Stock Exchange of India Results Update
NSE's press release reports Q2 FY27 consolidated PAT up 23% YoY to ₹2,578 crore. Total income rose 9% to ₹4,554 crore alongside the audited results.